MICURERX - Key Persons
Job Titles:
- CEO and Co - Founder of CUBIQ FOODS
- Head of Delivery Platform Technology
Andrés is the CEO and co-founder of CUBIQ FOODS (2018-present), a leading Spanish foodtech company. He is also Managing partner of Lingea Management & Consulting firm, supporting companies in Business development and Oligonucleotide delivery program development.
Before, as CEO, Senior Vice President, Research Head & Founder, of nLife Therapeutics (2006-2018, he has been involved in the development of oligonucleotides as therapeutic agents, published papers in the field of oligonculeotides for CNS therapies and issued the foundational patents. He holds a B.D. in Biotechnology from the Rosario University in Argentina and a PDD-2004 from IESE Business School (Spain).
Job Titles:
- Member of the Board
- Founding Partner of Investment One Partners
Bernardo Parnes, founding partner of Investment One Partners, has more than 30 years of experience leading renowned Brazilian and Global financial institutions. He was CEO for Latin America at Deutsche Bank and Chief Country Officer for Brazil.
He structured Banco Bradesco BBI S/A, and managed JSI Investimentos Ltda., Joseph Safra's family office. He was president of Merrill Lynch Brazil for more than 10 years, having started his career in finance at Citibank, where he worked for 7 years.
Job Titles:
- Chief Executive Officer
- CEO of MiCure
Dr. Fogelman became the CEO of miCure on June 1, 2022. She brings more than 30 years of experience in the development and due diligence of medical technologies (drugs, biologics and in-vitro diagnostics), including regulatory affairs (former FDA medical reviewer), clinical trial design and analysis, market research (former biotech equity analyst), and competitive Intelligence. Co-founder of C 2 N Diagnostics, a private company developing treatments and diagnostics for Alzheimer's Disease (C 2 N launched the PrecivityAD TM test, a blood test to aid in the diagnosis of Alzheimer's). As the COO of LifeTech Research, a consulting firm providing fundamental research to financial institutions, she conducted In-depth due diligence of more than 250 disruptive medical technologies across multiple therapeutic areas. Originally from Brazil, where she obtained her MD, followed by five years of training at Harvard where she obtained an MPH and completed two post-doctoral fellowships (in HIV clinical trials and cellular immunology).
Served as Vice President, Movement and Neuromuscular Disorders Clinical Development at Biogen Idec between 2014-2019. Prior to joining Biogen, Dr. Cedarbaum was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squibb, where he was responsible for late-stage programs in neurology and psychiatry.
He has also held senior clinical development positions at Cytokinetics, Elan and Regeneron.
J.R. Ferraz has 32 years of international experience in the healthcare industry leading organizations in a variety of segments such as Surgery, Specialty Pharma, E-commerce and retail OTC. He has held senior executive positions at Livanova plc, Nestle Health and Johnson & Johnson and had board experiences in Brazil and Internationally.
Mr. Ferraz holds bachelor's degree in Business Administration and post graduated in International Marketing and Finance, with both honors being from Fundação Getulio Vargas (FGV).
Former partner and manager of Banco Matrix S.A., where he worked for eight years. Lawyer and partner of law firms for more than ten years, performing in corporate and tax areas, capital markets and estate planning.
Former CFO of RXZ Investimentos, an investment company focused on listed and private equities. Mr. Horovitz was also a founding partner of two Brazilian Hedge Funds; Skopos Administradora de Recursos and VIX Investimentos. Mr. Horovitz holds a B.S. in Metallurgical Engineering from Universidade de São Paulo.
Mr. Fabio Jung graduated a medical school in the Federal University of Rio Grande do Sul
Roberto Ruhman is Brazilian, currently living in London, and has a professional career of more than 35 years of experience in financial markets, investment banking and asset management sectors, both as an executive and as an entrepreneur. He graduated from business school (Escola de Administração de Empresas de São Paulo - Fundação Getúlio Vargas).
His career began at Citibank N.A. Brasil, and he worked at Banco Safra S/A. In both institutions, he was a senior bank executive in two different stints.
Roberto started his entrepreneurial activity when he founded Indosuez Capital Emerging Markets. He later joined Banco Matrix S/A as a partner. Roberto next went on to found RXZ Investimentos Ltda., an investment company. Additionally, between 2013-17, Roberto was a member of J. Rothschild Capital Management Limited's Board of Directors. Currently, he is a founding partner of Joatinga Advisory UK Ltd, along with being the Chairman of the Board of miCure Therapeutics Ltd (an Israeli biotech start-up).
Mr. Manashirov was involved in the original miR-135 related research at Prof. Chen's lab and has been working in miCure since its foundation. He has over 10 years of research experience in the field of neurobiology and during his M.Sc. and Ph.D. studies at Prof. Chen's laboratory, his research focused on linking alteration in epigenetic mechanism and psychiatric disorders as well as identifying translatable targets for the clinic. He has been based in Barcelona since 2017.